



Atypical Antipsychotic Prior Authorization Form
Fee-for-Service Medicaid/PeachCare for Kids
PHONE #: 866-525-5827
FAX #: 888-491-9742

Note: If the following information is NOT filled in completely, correctly, or legibly the PA process **may** be delayed.
Please complete one form per member.

MEMBER Last Name <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	MEMBER First Name <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>
MEMBER ID number <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	MEMBER Date of Birth <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>
PRESCRIBER Last Name <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	PRESCRIBER First Name <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>
PRESCRIBER NPI# <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	
PRESCRIBER Phone <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	PRESCRIBER Fax <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>
PRESCRIBER Address <div style="border: 1px solid black; height: 1.2em; width: 100%;"></div>	

Medication Requested: _____ **Strength:** _____

Directions: _____ **Dosage Form:** _____ **Compound** ☐ Y ☐ N

What is the member's diagnosis? ☐ Bipolar Disorder ☐ Schizophrenia ☐ Schizoaffective Disorder
☐ Major Depressive Disorder ☐ Irritability associated with Autism
☐ Other (specify): _____

What is the member's age in years? ☐ ≥18 ☐ 10-17 ☐ 6-9 ☐ 5 ☐ <5

Is there a monitoring plan in place for evaluating safety and effectiveness of the medication? ☐ Yes ☐ No

NOTE: Section A or B must be completed.

**C
H
E
C
K

O
N
E

A

OR

B**

☐ **A. The member has been established on the requested medication**

- How long has the member been taking the requested medication?
☐ <2 weeks ☐ ≥2 weeks
- Has the member shown improvement in symptoms while on the requested medication?
☐ Yes ☐ No
 If yes, please check one or more boxes below for areas of improvement: ____

<input type="checkbox"/> delusions	<input type="checkbox"/> excitement	<input type="checkbox"/> conceptual disorganization
<input type="checkbox"/> grandiosity	<input type="checkbox"/> hostility	<input type="checkbox"/> hallucinatory behavior
<input type="checkbox"/> suspiciousness/persecution	<input type="checkbox"/> blunted affect	<input type="checkbox"/> emotional withdrawal
<input type="checkbox"/> passive/apathetic social withdrawal		<input type="checkbox"/> poor rapport
<input type="checkbox"/> difficulty in abstract thinking	<input type="checkbox"/> lack of spontaneity and flow of conversation	
<input type="checkbox"/> stereotyped thinking	<input type="checkbox"/> suicidal thoughts	<input type="checkbox"/> depressive symptoms
<input type="checkbox"/> other _____		

☐ **B. The member has never taken the requested medication**

- Which preferred medication(s) has the member tried? (check all that apply)
☐ Geodon Dates: _____ ☐ Risperidone Dates: _____
☐ Seroquel IR Dates: _____ ☐ None

2. Reason preferred agents are not appropriate for this member: (Complete for each drug in the following table)

Drug	Reason inappropriate choice for member
Risperidone	
Seroquel IR	
Geodon	

3. For Abilify and Seroquel XR (adjunctive therapy for major depressive disorder only): Reason antidepressant monotherapy is not adequate for this member: (Complete for each drug/class in the following table)

Drug	Reason antidepressant monotherapy is inadequate
Cymbalta (duloxetine)	
Effexor (venlafaxine)	
SSRIs (citalopram [Celexa], escitalopram [Lexapro], fluoxetine [Prozac], fluvoxamine [Luvox], paroxetine [Paxil], or sertraline [Zoloft])	

C
H
E
C
K

I
F

A
P
P
L
I
C
A
B
L
E

☐ **C. An orally disintegrating dosage formulation is being requested.**

1. What prevents the member from taking the regular oral dosage form?

☐ Dysphagia ☐ Compliance monitoring required

☐ Other (specify): _____

☐ **D. Risperdal Consta, Invega Sustenna, or Zyprexa Relprevv is being requested.**

1. Has the member tried oral risperidone or oral Invega (if Risperdal Consta is being requested), oral Invega, oral risperidone, or Risperdal Consta (if Invega Sustenna is being requested), or oral Zyprexa (if Zyprexa Relprevv is being requested) or does the member have a history of noncompliance with oral medications and is unable to receive a trial of the appropriate oral atypical antipsychotic before starting long-acting therapy with injection or is the member unable to swallow or use orally disintegrating tablets?

☐ Yes Date of last therapy: _____ ☐ No

2. Is the prescribing physician a psychiatrist or has a psychiatrist been consulted?

☐ Yes ☐ No

3. Where will the medication be administered?

☐ Home health

☐ CSB (Community Service Board health center)

☐ Outpatient clinic or physician's office**

☐ Other (specify): _____

** If you are requesting for authorization for administration in a physician's office or outpatient clinic other than a CSB, please go to the Registered User portion of the Georgia Health Partnership website at www.mmis.georgia.gov/portal to request a PA from Physician Services.

Physician Signature: _____

Contact Person: _____ Phone: _____

SXC Health Solutions, Inc. will provide a response within 1 business day upon receipt.

This facsimile transmission contains legally privileged and confidential information intended for the parties identified below. If you have received this transmission in error, please immediately notify us by telephone and return the original message to P.O. Box 3214; Lisle, IL 60532-8214. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.